278 related articles for article (PubMed ID: 30718006)
1. Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients.
Liu B; Wang Y; Bai M; Wang D; Zhao J; Zhang M; Sun S
Clin Ther; 2019 Jun; 41(6):1186-1198. PubMed ID: 30718006
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of cyclophosphamide, thalidomide and dexamethasone (CTD) versus bortezomib and dexamethasone (BDex) in light-chain amyloidosis.
Liu B; Wang Y; Ning X; Bai M; Wang D; Zhao J; Zhou M; Sun S
Curr Probl Cancer; 2021 Apr; 45(2):100669. PubMed ID: 33127168
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.
Wechalekar AD; Goodman HJ; Lachmann HJ; Offer M; Hawkins PN; Gillmore JD
Blood; 2007 Jan; 109(2):457-64. PubMed ID: 16990593
[TBL] [Abstract][Full Text] [Related]
4. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.
Venner CP; Gillmore JD; Sachchithanantham S; Mahmood S; Lane T; Foard D; Rannigan L; Gibbs SD; Pinney JH; Whelan CJ; Lachmann HJ; Hawkins PN; Wechalekar AD
Leukemia; 2014 Dec; 28(12):2304-10. PubMed ID: 25027514
[TBL] [Abstract][Full Text] [Related]
5. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of systemic AL amyloidosis: about 25 cases].
Eddou H; Zinebi A; Maaroufi HE; Moudden MK; Doghmi K; Mikdame M; Baaj ME
Pan Afr Med J; 2017; 28():160. PubMed ID: 29541306
[TBL] [Abstract][Full Text] [Related]
7. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
Palladini G; Russo P; Foli A; Milani P; Lavatelli F; Obici L; Nuvolone M; Brugnatelli S; Invernizzi R; Merlini G
Ann Hematol; 2012 Jan; 91(1):89-92. PubMed ID: 21533608
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
Dinner S; Witteles W; Afghahi A; Witteles R; Arai S; Lafayette R; Schrier SL; Liedtke M
Haematologica; 2013 Oct; 98(10):1593-9. PubMed ID: 23716538
[TBL] [Abstract][Full Text] [Related]
9. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
Palladini G; Milani P; Foli A; Basset M; Russo F; Perlini S; Merlini G
Blood; 2018 Feb; 131(5):525-532. PubMed ID: 29101236
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
Adam Z; Pour L; Krejcí M; Zahradová L; Krivanová A; Mardová J; Kovárová L; Stepánková S; Moulis M; Kren L; Veselý K; Svobodová I; Germáková Z; Nedbálková M; Mayer J; Hájek R
Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
[TBL] [Abstract][Full Text] [Related]
11. [Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
Pika T; Lochman P; Vymětal J; Metelka R; Minařík J; Látalová P; Zapletalová J; Bačovský J; Ščudla V
Klin Onkol; 2013; 26(5):343-7. PubMed ID: 24107157
[TBL] [Abstract][Full Text] [Related]
12. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
Ahn JS; Yang DH; Jung SH; Park HC; Moon JH; Sohn SK; Bae SY; Kim YK; Kim HJ; Lee JJ;
Ann Hematol; 2012 Jul; 91(7):1023-30. PubMed ID: 22314843
[TBL] [Abstract][Full Text] [Related]
13. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Pamboukas C; Boletis I; Marinaki S; Apostolou T; Nikitas N; Gkortzolidis G; Michalis E; Delimpasi S; Dimopoulos MA
Blood; 2012 Jun; 119(23):5384-90. PubMed ID: 22517904
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
15. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Charliński G; Wiater E; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: a retrospective single-center study.
Katoh N; Ueno A; Yoshida T; Tazawa KI; Shimojima Y; Gono T; Sekijima Y; Matsuda M; Ikeda SI
Int J Hematol; 2017 Mar; 105(3):341-348. PubMed ID: 27832515
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
Vigolo S; Zuckermann J; Bittencourt RI; Silla L; Pilger DA
Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):135-142. PubMed ID: 28636891
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
Hegenbart U; Bochtler T; Benner A; Becker N; Kimmich C; Kristen AV; Beimler J; Hund E; Zorn M; Freiberger A; Gawlik M; Goldschmidt H; Hose D; Jauch A; Ho AD; Schönland SO
Haematologica; 2017 Aug; 102(8):1424-1431. PubMed ID: 28522573
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
Kumar SK; Hayman SR; Buadi FK; Roy V; Lacy MQ; Gertz MA; Allred J; Laumann KM; Bergsagel LP; Dingli D; Mikhael JR; Reeder CB; Stewart AK; Zeldenrust SR; Greipp PR; Lust JA; Fonseca R; Russell SJ; Rajkumar SV; Dispenzieri A
Blood; 2012 May; 119(21):4860-7. PubMed ID: 22504925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]